{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:37:42Z","timestamp":1778701062236,"version":"3.51.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the feasibility, safety, and potential association between hyperthermic intraperitoneal chemotherapy (HIPEC) and peritoneal recurrence in patients with locally advanced gastric cancer following D2 radical surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A retrospective analysis was conducted on 156 patients with locally advanced gastric cancer treated with D2 surgery at two centers between 2014 and 2023. Clinical outcomes and adverse events were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline characteristics were comparable between the HIPEC group (n = 70) and the surgery-only group (n = 86). The 2-year peritoneal recurrence rate was lower in the HIPEC group (18.6% vs. 34.9%, <jats:italic>P<\/jats:italic>=0.0206). Several factors\u2014including high Charlson Comorbidity Index, advanced T stage, vascular invasion, intraoperative blood loss, and absence of HIPEC\u2014were associated with higher recurrence risk. No significant differences were observed in perioperative complications between the groups or among different HIPEC frequencies (all <jats:italic>P<\/jats:italic> &amp;gt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this real-world dual-center study, HIPEC following D2 surgery was found to be feasible and safe, and was associated with a reduced risk of peritoneal recurrence in patients with locally advanced gastric cancer. These observational findings warrant further validation in randomized controlled trials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1498388","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:16:49Z","timestamp":1757391409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the feasibility, safety, and preliminary effectiveness of hyperthermic intraperitoneal chemotherapy following radical surgery for locally advanced gastric cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Tianze","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18457","article-title":"Global incidence and mortality of gastric cancer, 1980 - 2018","volume":"4","author":"Wong","year":"2021","journal-title":"JAMA network Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213689","article-title":"Prognostic value of neutrophil-to-eosinophil ratio (Ner) in cancer: A systematic review and meta-analysis","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101835","article-title":"Prognostic significance of the royal marsden hospital (Rmh) score in patients with cancer: A systematic review and meta-analysis","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","article-title":"Immune checkpoint inhibitor-related hearing loss: A systematic review and analysis of individual patient data","volume":"31","author":"Guven","year":"2023","journal-title":"Supportive Care cancer: Off J Multinational Assoc Supportive Care Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"28309","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the mouseion-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, nccn clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-017-0716-7","article-title":"Five-year survival analysis of surgically resected gastric cancer cases in Japan: A retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese gastric cancer association (2001 - 2007)","volume":"21","author":"Katai","year":"2018","journal-title":"Gastric cancer: Off J Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5838-y","article-title":"Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy","volume":"24","author":"Ikoma","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S - 1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"New Engl J Med"},{"key":"B12","article-title":"Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies","volume":"50","author":"Sugarbaker","year":"1990","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.04.150","article-title":"Analysis of factors associated with outcome in patients with Malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy","volume":"21","author":"Feldman","year":"2003","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.09.024","article-title":"Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases","volume":"50","author":"Elias","year":"2014","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i30.6906","article-title":"Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal Malignancies","volume":"22","author":"Li","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9","article-title":"Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma","volume":"85","author":"Fujimoto","year":"1999","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2002.123769","article-title":"Lack of efficacy of prophylactic continuous hyperthermic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer","volume":"131","author":"Kunisaki","year":"2002","journal-title":"Surgery"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/mlr.0000000000000471","article-title":"The best use of the charlson comorbidity index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-06-1735","article-title":"Phase I trial of intraperitoneal gemcitabine in the treatment of advanced Malignancies primarily confined to the peritoneal cavity","volume":"13","author":"Morgan","year":"2007","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B21","article-title":"Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans","volume":"41","author":"Speyer","year":"1981","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01688","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (Cyto-chip study): A propensity score analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11912-018-0703-0","article-title":"Peritoneal metastases from gastrointestinal cancer","volume":"20","author":"Sugarbaker","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","article-title":"Intraperitoneal chemotherapy in advanced gastric cancer","volume":"40","author":"Coccolini","year":"2014","journal-title":"Meta-Analysis Randomized Trials. Eur J Surg oncology: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-013-0306-2","article-title":"Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy","volume":"17","author":"Lee","year":"2014","journal-title":"Gastric cancer: Off J Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2013_023","article-title":"D2 lymphadenectomy can disseminate tumor cells into peritoneal cavity in patients with advanced gastric cancer","volume":"60","author":"Yu","year":"2013","journal-title":"Neoplasma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.01.13","article-title":"Risk-stratification model to select conversion surgery for advanced gastric cancer patients","volume":"31","author":"Nie","year":"2019","journal-title":"Chin J Cancer Res = Chung-kuo yen cheng yen chiu"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5223-2","article-title":"Significant role of palliative gastrectomy in selective gastric cancer patients with peritoneal dissemination: A propensity score matching analysis","volume":"23","author":"Nie","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2022.2028018","article-title":"A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-iii gastric cancer","volume":"39","author":"Liu","year":"2022","journal-title":"Int J hyperthermia: Off J Eur Soc Hyperthermic Oncology North Am Hyperthermia Group"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2204","article-title":"Hyperthermic intraperitoneal chemotherapy (Hipec) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: A retrospective cooperative central-eastern european study","volume":"8","author":"Yarema","year":"2019","journal-title":"Cancer Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05019-z","article-title":"Hyperthermic intraperitoneal chemotherapy (Hipec) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: A randomized-controlled study","volume":"149","author":"Yu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02867","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase iii gastripec-I trial","volume":"42","author":"Rau","year":"2024","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000000457","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on survival and recurrence rates in advanced gastric cancer: A systematic review and meta-analysis","volume":"109","author":"Patel","year":"2023","journal-title":"Int J Surg (London England)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.07.030","article-title":"Hyperthermic intraperitoneal chemotherapy in serosa-invasive gastric cancer patients","volume":"45","author":"Reutovich","year":"2019","journal-title":"Eur J Surg oncology: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/000313480006600607","article-title":"Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin","volume":"66","author":"Loggie","year":"2000","journal-title":"Am surgeon"},{"key":"B36","article-title":"Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study","volume":"48","author":"Yonemura","year":"2001","journal-title":"Hepato-gastroenterology"},{"key":"B37","first-page":"39","article-title":"Gene expression changes induced by hipec in a murine model of gastric cancer","volume":"26","author":"Graziosi","year":"2012","journal-title":"In Vivo (Athens Greece)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-2-112","article-title":"Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy","volume":"10","author":"Sugarbaker","year":"2005","journal-title":"oncologist"},{"key":"B39","doi-asserted-by":"publisher","first-page":"Cd004064","DOI":"10.1002\/14651858.CD004064.pub3","article-title":"Chemotherapy for advanced gastric cancer","author":"Wagner","year":"2010","journal-title":"Cochrane Database systematic Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1245\/s10434-009-0669-0","article-title":"Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo","volume":"17","author":"Cohen","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.03.024","article-title":"Severe postoperative complications decrease overall and disease free survival in pancreatic ductal adenocarcinoma after pancreaticoduodenectomy","volume":"44","author":"Lubrano","year":"2018","journal-title":"Eur J Surg oncology: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12893-022-01795-6","article-title":"Hyperthermic intraperitoneal chemotherapy for patients with gastric cancer based on laboratory tests is safe: A single chinese center analysis","volume":"22","author":"Wu","year":"2022","journal-title":"BMC Surg"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07450-4","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (Hipec) for gastric cancer with peritoneal carcinomatosis: multicenter study of spanish group of peritoneal oncologic surgery (Gecop)","volume":"26","author":"Manzanedo","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000520330","article-title":"Comparative analysis of postoperative complications after cytoreductive surgery and hipec in gastric cancer","volume":"45","author":"Merboth","year":"2022","journal-title":"Oncol Res Treat"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1109633","article-title":"Single versus multiple hyperthermic intraperitoneal chemotherapy applications for T4 gastric cancer patients: efficacy and safety profiles","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase iii randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3327-5","article-title":"Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23889","article-title":"Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis","volume":"111","author":"Wu","year":"2015","journal-title":"J Surg Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25094","article-title":"Repeat staging laparoscopy for gastric cancer after preoperative therapy","volume":"118","author":"Thiels","year":"2018","journal-title":"J Surg Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11072003","article-title":"Prognostic significance of pd-L1 expression in gastric cancer patients with peritoneal metastasis","volume":"11","author":"Chen","year":"2023","journal-title":"Biomedicines"},{"key":"B51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","article-title":"Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study","volume":"36","author":"Qi","year":"2024","journal-title":"Chin J Cancer Res = Chung-kuo yen cheng yen chiu"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.133247","article-title":"Her-2 positive gastric cancer: current targeted treatments","volume":"274","author":"Malla","year":"2024","journal-title":"Int J Biol macromolecules"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174142","article-title":"Adjuvant pd-1 and pd-L1 inhibitors and relapse-free survival in cancer patients: the mouseion-04 study","volume":"14","author":"Rizzo","year":"2022","journal-title":"Cancers"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i32.11347","article-title":"Microrna-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2024.2310017","article-title":"Impacts of hyperthermic chemotherapeutic agent on cytotoxicity, chemoresistance-related proteins and pd-L1 expression in human gastric cancer cells","volume":"41","author":"Su","year":"2024","journal-title":"Int J hyperthermia: Off J Eur Soc Hyperthermic Oncology North Am Hyperthermia Group"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26366","article-title":"Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the periscope I trial","volume":"123","author":"Koemans","year":"2021","journal-title":"J Surg Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1186\/s12885-020-07339-6","article-title":"Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: A retrospective clinical study","volume":"20","author":"Zhu","year":"2020","journal-title":"BMC Cancer"},{"key":"B58","article-title":"The role of prophylactic hyperthermic intraperitoneal chemotherapy in the management of serosal involved gastric cancer","volume":"34","author":"Saladino","year":"2014","journal-title":"Anticancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12885-021-07925-2","article-title":"Phase ii trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery","volume":"21","author":"Fan","year":"2021","journal-title":"BMC Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2013.3640","article-title":"Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program","volume":"149","author":"Jafari","year":"2014","journal-title":"JAMA Surg"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2013.768359","article-title":"Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (Ihic) for gastric cancer: A systematic review and meta-analysis of randomised controlled trials","volume":"29","author":"Mi","year":"2013","journal-title":"Int J hyperthermia: Off J Eur Soc Hyperthermic Oncology North Am Hyperthermia Group"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2015.03.008","article-title":"Hyperthermic intraperitoneal chemotherapy + Early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis","volume":"210","author":"Lam","year":"2015","journal-title":"Am J Surg"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.08.006","article-title":"Guidelines for Perioperative Care in Cytoreductive Surgery (Crs) with or without Hyperthermic Intraperitoneal Chemotherapy (Hipec): Enhanced Recovery after Surgery (Eras\u00ae) Society Recommendations - Part Ii: Postoperative Management and Special Considerations","volume":"46","author":"H\u00fcbner","year":"2020","journal-title":"Eur J Surg oncology: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10376-5","article-title":"Hipec-induced acute kidney injury: A retrospective clinical study and preclinical model","volume":"29","author":"Liesenfeld","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.07.016","article-title":"Hyperthermic intraperitoneal chemotherapy with cisplatin: amifostine prevents acute severe renal impairment","volume":"42","author":"Bouhadjari","year":"2016","journal-title":"Eur J Surg oncology: J Eur Soc Surg Oncol Br Assoc Surg Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1498388\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:16:50Z","timestamp":1757391410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1498388\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":65,"alternative-id":["10.3389\/fonc.2025.1498388"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1498388","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"article-number":"1498388"}}